Ovagen
Liver and gastrointestinal bioregulator peptide from the Khavinson series. Short peptide (2-4 amino acids) that targets specific tissue for gene expression regulation and organ health optimization.
Research Status
Limited Clinical Data
For research purposes only. Not approved for human use. Not medical advice.
Research Areas
Side Effects
Mild erythema, swelling, or itching at the injection site may occur. Usually resolves within 1-2 hours. Ensure proper site rotation and sterile injection technique to minimize risk. Apply ice if needed.
Mild nausea, bloating, or changes in bowel habits have been reported in some users, particularly when starting therapy. Usually self-resolving within 3-7 days. Take with food if tolerated.
Occasional mild headache reported in early treatment phase. Typically resolves with continued use or dose adjustment. Ensure adequate hydration.
Although rare, hypersensitivity reactions (rash, urticaria, angioedema, or anaphylaxis) are theoretically possible. Discontinue immediately and seek medical attention if signs of allergy develop. Do not use if allergic to peptides or animal-derived products.
Isolated reports of transient dizziness. Sit or lie down if this occurs. Ensure adequate hydration and food intake.
Dosing Reference
| Parameter | Value |
|---|---|
| Dose range | 10-20 mcg |
| Frequency | 1-2x daily |
| Timing | Morning and/or evening, sublingual or subcutaneous |
| Route | Subcutaneous |
Khavinson bioregulator peptide. Start at lower dose (10 mcg) and assess tolerance. Sublingual administration allows direct mucosal absorption; subcutaneous provides systemic delivery. Limited Western clinical trial data; primarily studied in Russian and Eastern European populations.
Research disclaimer
Figures drawn from published research literature and community logs. Not clinical recommendations. Consult a qualified professional. Research use only.
Reconstitution Guide
Do not use saline or bacteriostatic saline — use only bacteriostatic water for reconstitution
Do not shake the vial vigorously; gentle swirling prevents peptide degradation
Discard immediately if the solution appears cloudy, discolored, or contains visible particles
Use within 30 days of reconstitution when stored at 2–8°C
Do not freeze the reconstituted solution; freezing may denature the peptide
Use the PeptideVolt reconstitution calculator for your exact concentration
Molecular and Pharmacological Data
Ovagen is a short-chain peptide bioregulator (2-4 amino acids) derived from liver and gastrointestinal tissue that acts as a tissue-specific gene expression modulator. It is proposed to enhance hepatic detoxification pathways and support gastrointestinal mucosal integrity through selective activation of organ-specific transcription factors and growth factors. The peptide is theorized to work via receptor-mediated signaling and epigenetic mechanisms that promote tissue-specific protein synthesis and cellular regeneration.
Hepatic Gene Expression Regulation
Ovagen is proposed to selectively upregulate genes encoding hepatic detoxification enzymes (Phase I, II, and III) and antioxidant proteins, enhancing the liver's capacity to metabolize xenobiotics and reduce oxidative stress.
Gastrointestinal Mucosal Integrity
The peptide may promote tight junction protein expression and stimulate mucin secretion in the GI epithelium, supporting the intestinal barrier and reducing pathogenic translocation.
Tissue-Specific Growth Factor Signaling
Ovagen is theorized to activate growth factor receptors (such as HGF or FGF pathways) in a tissue-selective manner, promoting hepatocyte and enterocyte proliferation and regeneration.
Oxidative Stress Reduction
The peptide may enhance expression of antioxidant enzymes (SOD, catalase, glutathione peroxidase) in liver and GI tissues, reducing reactive oxygen species and supporting cellular homeostasis.
- Ovagen is part of the Khavinson bioregulator series, a class of short peptides derived from animal tissues with organ-specific activity
- The peptide is proposed to work through gene expression modulation rather than direct enzymatic activity
- Tissue specificity is a defining characteristic — Ovagen targets liver and GI tissues preferentially
- Most published data on Ovagen comes from Russian and Eastern European research; Western clinical trials are limited
- The exact amino acid sequence and precise molecular targets have not been fully disclosed in peer-reviewed literature
Track your Ovagen research
Free account. No credit card required.
Browse the Research Library
40+ peptide profiles with mechanism summaries, dosing data, and reconstitution guides.
View all peptidesResearch Use Only. All content on this page is provided for informational and educational purposes related to scientific research. Ovagen is not approved for human use by the FDA or any equivalent regulatory body. This is not medical advice. Do not use any substance discussed here for therapeutic, diagnostic, or preventative purposes. Consult a qualified healthcare professional before making any health-related decisions. The Peptide Volt does not endorse the use of any research chemicals. 18+ only.